CAS 1029044-16-3: Plx 3397

Description:PLX 3397, with the CAS number 1029044-16-3, is a small molecule inhibitor primarily targeting the receptor tyrosine kinases (RTKs) such as c-KIT, PDGFR, and FLT3. It is notable for its role in cancer research, particularly in the treatment of various malignancies, including those associated with mutations in these kinases. PLX 3397 exhibits a selective inhibition profile, which helps to minimize off-target effects, making it a candidate for targeted therapy. The compound is typically administered orally and has been evaluated in clinical trials for its efficacy and safety in treating tumors. Its mechanism of action involves blocking the signaling pathways that promote tumor growth and survival, thereby inducing apoptosis in cancer cells. Additionally, PLX 3397 has shown potential in modulating the tumor microenvironment, which can enhance the effectiveness of other therapeutic agents. As with many investigational drugs, ongoing research continues to elucidate its full pharmacological profile and therapeutic potential.

Formula:C₂₀H₁₅ClF₃N₅

InChI:InChI=1S/C20H15ClF3N5/c21-15-6-16-14(10-28-19(16)29-11-15)5-12-2-4-18(26-7-12)27-9-13-1-3-17(25-8-13)20(22,23)24/h1-4,6-8,10-11H,5,9H2,(H,26,27)(H,28,29)

InChI key:InChIKey=JGWRKYUXBBNENE-UHFFFAOYSA-N

SMILES:FC(F)(F)C1=NC=C(C=C1)CNC2=NC=C(C=C2)CC3=CNC=4N=CC(Cl)=CC43

Found 5 products.

Product data	Purity	Price range	Estimated delivery
N-[5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-2-pyridinyl]-6-(trifluoromethyl)-3-pyridinemethanamine REF: IN-DA0039N8CAS: 1029044-16-3	98%	34.00 €~669.00 €	Mon 03 Mar 25
Pexidartinib REF: 7W-GP8518CAS: 1029044-16-3	≥ 98.0%	To inquire	Tue 04 Mar 25
Pexidartinib (PLX3397) REF: 4Z-K-031070CAS: 1029044-16-3	- - -	To inquire	Mon 10 Mar 25
Pexidartinib REF: TM-T2115CAS: 1029044-16-3	98.59% - 99.66%	48.00 €~2,264.00 €	Mon 10 Mar 25
Pexidartinib REF: 3D-FP76492CAS: 1029044-16-3	Min. 95%	196.00 €~1,050.00 €	Wed 12 Mar 25